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Abstract: Malignant pleural mesothelioma (MPM) is a lethal cancer with limited treatment options.
No targeted therapy has emerged yet. Here, we performed an integrated molecular characterization
of patient tumors in the TCGA dataset, and discovered that endoplasmic reticulum (ER) stress
and the adaptive unfolded protein response (UPR) signaling are characteristically deregulated in
MPM. Consequently, pharmacological perturbation of ER stress/UPR axis by HA15, an agent that
induces persistent proteotoxic stress in the ER, selectively suppresses the viability of MPM cells
including those refractory to standard chemotherapy. Mechanically, HA15 augments the already
high basal level of ER stress in MPM cells, embarks pro-apoptotic malfunctional UPR and autophagy,
which eventually induces cell death in MPM. Importantly, HA15 exerts anti-MPM effectiveness in a
mouse model of patient-derived xenografts (PDX) without eliciting overt toxicity when compared to
chemotherapy. Our results revealed that programs orchestrating ER stress/UPR signaling represent
therapeutic vulnerabilities in MPM and validate HA15 as a promising agent to treat patients with
MPM, naïve or resistant to chemotherapy.
Keywords: malignant pleural mesothelioma (MPM); endoplasmic reticulum (ER) stress; unfolded
protein response (UPR); HA15; autophagy
1. Introduction
Malignant pleural mesothelioma (MPM) is a rare but aggressive cancer [1,2], consisting of
epithelioid, mixed (biphasic) and sarcomatoid histological subtypes [3]. Despite progress in the
understanding of the disease etiology, clinical management of MPM patients remains a significant but
unmet challenge [4]. Whereas aggressive surgery is amenable for early-stage tumors [5], a majority
(80%) of patients with MPM are diagnosed at advanced stages, for which a dual chemotherapy regimen
that combines cisplatin and pemetrexed is the only clinically approved therapy [6]. However, this
systemic treatment only mildly improves patient survival (by three months only), as drug resistance,
de novo, and/or acquired after the treatment, prevails [7].
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Comprehensive genomic studies revealed that MPM is predominantly driven by loss of function
mutations in tumor suppressor genes, most commonly the cyclin-dependent kinase inhibitor 2A/2B
gene (CDKN2A/2B), BRCA1 associated protein 1 gene (BAP1), neurofibromin 2 gene (NF2), whereas
therapeutically tractable oncogenic drivers are rare [8–10]. The lack of druggable activating
mutations [9,11,12] have significantly hampered the development of targeted therapies for MPM,
which, however, suggests the importance of identifying and targeting functional cancer dependencies
rather than specific driver mutations to combat MPM.
Cancer cells evolve in response to changes in oncogenic signaling and environmental pressures,
for example, exacerbated secretory capacity, genomic instability and hypoxia [13,14]. Many
stress-responsive mechanisms converge at an anabolic switch that increases protein metabolism,
which induces proteotoxic endoplasmic reticulum (ER) stress, and in turn invokes the unfolded
protein response (UPR) [15–17]. The UPR is mediated by three major signaling cascades initiated
by so-called ER stress sensors: double-stranded RNA-activated protein kinase (PKR)-like ER kinase
(PERK), inositol-requiring enzyme 1α (IRE1α), and activating transcription factor 6 (ATF6). PERK,
IRE1α, and ATF6 are ER membrane proteins that, at the steady state, are complexed with the
chaperone protein glucose-regulated protein 78 (GRP78, also known as BiP). When threatened by
increased protein-folding demand (ER stress), BiP is released, which activates PERK, IRE1α, and
ATF6, and in turn, their downstream effectors to alleviate proteotoxic stress placed on the ER and to
restore ER homoeostasis [18]. However, if the stress is irresolvable, the UPR signaling will trigger
apoptosis/autophagy, leading to cell death [19,20].
UPR dysfunction is implicated in many human diseases, for example, neurodegenerative,
cardiovascular, and metabolic disorders. Hyperactive UPR has been reported in Alzheimer’s
disease (AD), progressive supranuclear palsy, and familial FTD (frontotemporal degeneration) with
parkinsonism linked to chromosome 17 [21]. Recent studies have also uncovered that chronic ER stress
is linked with endothelial dysfunction in cardiovascular diseases by increasing oxidative stress [22], and
with insulin resistance and increased lipogenesis involved in metabolic disorders such as type II diabetes
and obesity [23]. Deregulation of ER stress/UPR is also not uncommon in cancers [24,25] and many
rely on the stress response signaling for survival or evasive resistance to cytotoxic therapeutics [26].
As such, targeting the UPR has emerged as a promising strategy for cancer therapy [27,28].
A recent study by Cerezo et al., identified a new ER stress amplifier, termed HA15. HA15 binds
to and inhibits the ATPase activity of BiP, thereby dissociating BiP from PERK, IRE1α, and ATF6
and triggering ER stress [29]. The anti-tumor effects of HA15 has been demonstrated in a variety of
human cancers including melanoma, breast, pancreas, and adrenocortical carcinoma [29,30]. In this
study, we showed that deregulation of ER stress/UPR signaling is a hallmark of MPM, which confers a
specific vulnerability of therapeutic potential. Consequently, MPM cells, regardless of chemo-naïve
or -resistant, are particularly susceptible to HA15. We further demonstrated that the antitumor effect
of HA15 is attributable to its ability to induce excessive proteotoxic stress in the ER, which initiates
malfunctional UPR, autophagy, and eventually the onset of apoptosis.
2. Results
2.1. ER Stress and the Adaptive UPR Is Deregulated in Patients’ MPM
To unravel cellular pathways that may represent specific dependencies of MPM, we performed
an integrated analysis of patients’ MPM based on transcriptomic and clinical data available at the
Cancer Genome Atlas (TCGA) [31]. Gene enrichment set analysis (GESA) revealed that genes involved
in ER stress and the adaptive UPR (UPR gene signature) were significantly enriched in the patients’
tumors compared to normal lung/pleura tissues (Figure 1A). Consistently, the UPR gene signature
was positively correlated with proliferation and resistance to apoptosis, assessed by the expression of
PCNA and BIRC5, encoding the proliferative marker proliferating cell nuclear antigen (PCNA) and
anti-apoptotic protein SURVIVIN (also called baculoviral inhibitor of apoptosis repeat-containing 5 or
Cancers 2019, 11, 1502 3 of 19
BIRC5), respectively (Figure 1B). Notably, the UPR gene signature is of predictive value for patients
with MPM, with an elevated UPR signature associated with poor prognosis (Figure 1C). Further
examination of the transcriptomic data of patient-derived MPM [32] revealed that numerous genes
involved in ER-related functions and/or proteostatic processes (i.e., FKBP14 [peptidyl-prolyl cis-trans
isomerase (PPIase) FKBP14], SSR1 (translocon-associated protein subunit alpha or TRAPα), HSP90B1
(heat shock protein 90 beta family member 1) and HSPA5/GRP78 (BiP)) are expressed at high levels in
MPM compared to normal tissues (Figure 1D). Of particular interest, HSPA5/GRP78 and its protein
product BiP, a key ER chaperone and a master regulator of ER stress and the adaptive UPR, were
generally overexpressed in MPM cells, except for H28, which had a lower BiP protein level than Met-5A
(Figure 1E,F). Thus, deregulation of ER stress/UPR signaling is a characteristic feature for MPM and
associated with poor prognosis in MPM patients. The original pictures of Western blotting can be
found in Figure S1.
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Figure 1. Endoplasmic reticulum (ER) stress/unfolded protein response(UPR) signaling is 
deregulated in malignant pleural mesothelioma (MPM). (A) Gene set enrichment analysis (GSEA) of 
the dataset (GSE2549) revealed significant enrichment of UPR in MPM tumor samples. (B) The UPR 
gene signature was positively correlated with the proliferative marker PCNA and anti-apoptotic 
marker SURVIVIN/BIRC5. Gene expression data of MPM were downloaded from TCGA, with 
Pearson/Spearman coefficients and p-value determined using R (version 3.4.3). (C) Kaplan-Meier 
analysis of a TCGA cohort of MPM patients (n = 86). The UPR gene signature was dichotomized based 
on the optimal cut-off value, and patient survival data were extracted for further analysis using R 
(Version 3.4.3). The p-value was calculated by the log-rank test. (D) The volcano plot of transcriptional 
comparison between the patients’ MPM vs. normal lung tissues (GSE51024). (E) Heatmap of key UPR 
gene expression (TPM) in the MPM cell lines. The expression profile was obtained from the European 
Bioinformatics Institute of European Molecular Biology Laboratory (EMBL-EBI). (F) Immunoblots of 
BiP in normal mesothelial cells (Met-5A) and MPM cell lines. Relative expression of BiP is shown 
underneath, with signal intensity quantified by ImageJ and normalized to the loading control (β-
actin). The value in the Met-5A was set as 1. 
2.2. Excessive ER Stress Induced by HA15 Selectively Impairs MPM Cells  
To address if ER stress/UPR signaling can be a potential therapeutic target in MPM, we treated 
a panel of cells including MPM cell lines across all histological subtypes (MESO-1, MESO-4, H28, JL-
1, MSTO-211H, and H2052), a primary MPM culture (BE261T) and non-transformed normal cells 
(hFb16lu, Met-5A), with HA15, an agent inducing excess ER stress by specifically targeting BiP [29]. 
HA15 preferentially suppressed cell viability of MPM cells, with the 50% inhibitory concentration 
(IC50) ranging from 5.71 to 20.51 µM, whereas it only mildly affected Met-5A and hFb16lu cells (Figure 
2A,B). Clonogenic assay confirmed that HA15 is far more deleterious for MPM cells than fibroblast 
hFb16lu and mesothelial Met-5A cells (Figures 2C–E). These results suggest that targeting BiP by 
HA15 preferentially inhibits MPM cells and is therefore a potential therapeutic strategy for MPM. 
 
Figure 1. Endoplasmic reticulum (ER) stress/unfolded protein response (UPR) signaling is deregulated
in malignant pleural mesothelioma (MPM). (A) Gene set enrichment analysis (GSEA) of the
dataset (GSE2549) revealed significant enrichment of UPR in MPM tumor samples. (B) The UPR
gene signature was positively correlated with the proliferative marker PCNA and anti-apoptotic
marker SURVIVIN/BIRC5. Gene expression data of MPM were downloaded from TCGA, with
Pearson/Spearman coefficients and p-value determined using R (version 3.4.3). (C) Kaplan-Meier
analysis of a TCGA cohort of MPM patients (n = 86). The UPR gene signature was dichotomized based
on the optimal cut-off value, and patient survival data were extracted for further analysis using R
(Version 3.4.3). The p-value was calculated by the log-rank test. (D) The volcano plot of transcriptional
comparison between the patients’ MPM vs. normal lung tissues (GSE51024). (E) Heatmap of key UPR
gene expression (TPM) in the MPM cell lines. The expression profile was obtained from the European
Bioinformatics Institute of European Molecular Biology Laboratory (EMBL-EBI). (F) I munoblots of
BiP in normal mesothelial cells (Met-5A) and MPM cell lines. Relative expression of BiP is shown
underneath, with signal intensity quantified by ImageJ and normalized to the loading control (β-actin).
The value in the Met-5A was set as 1.
2.2. Excessive ER Stress Induced by HA15 Selectively Impairs MPM Cells
To address if ER stress/UPR signaling can be a potential therapeutic target in MPM, we treated
a panel of cells including MPM cell lines across all histological subtypes (MESO-1, MESO-4, H28,
JL-1, MSTO-211H, and H2052), a primary MPM culture (BE261T) and non-transformed normal cells
(hFb16lu, Met-5A), with HA15, an agent inducing excess R stress by specifically targeting BiP [29].
HA15 prefer ntially suppressed cell viability of MPM cells, with the 50% inhibitory concentration
(IC50) ranging from 5.71 to 20.51 µM, whereas it only mildly affected Met-5A and hFb16lu cells
(Figure 2A,B). Clonogenic assay confirm d that HA15 is f r more d leterious for MPM cells than
fibroblast hFb16lu and mes thelial Met-5A cells (Figure 2C–E). These results suggest that t rgeting BiP
by HA15 preferentially inhibits MPM cells and is therefore a pot ntial therapeutic str tegy for M M.
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treated with HA15. Colonies were stained and quantified (right panel) after 14 days. Representative 
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Figure 2. Excess ER stress induced by HA15 selectively inhibits MPM cells. (A,B) Cell viability and
IC50 of normal human lung fibroblasts (hFb16Lu), normal human mesothelial (Met-5A), and MPM
cells after treatment with HA15 for 72 h. Data are presented as mean ± s.d. A representative result is
presented (n = 2). (C–E) Clonogenic assay of MPM cell lines (C), primary MPM culture (BE261T) (D),
normal human lung fibroblasts (hFb16Lu), and normal human mesothelial (Met-5A) after being treated
with HA15. Colonies were stained and quantified (right panel) after 14 days. Representative images of
three independent experiments (n = 3) are shown. Quantification (E) was based on the results of (C) and
(D). Data are presented as mean ± s.d. (n = 3). # p < 0.05, #### p < 0.0001 by two-way ANOVA with
Dunnett’s multiple comparisons test, when compared with hFb16Lu. * p < 0.05, ** p < 0.01, *** p < 0.005,
and **** p < 0.0001 by two-way ANOVA with Dunnett’s multiple comparisons test, when compared
with Met-5A.
2.3. Activation of Malfu ctional UPR and Aut ph gy Underpins HA15 Effectiveness in MPM Cells
Next, we addressed the molecular underpinnings of HA15 effects in MPM. HA15 induced
persistent ER stress in MPM cells, measured by increased expression of key UPR genes [EIF2AK3
(PERK), ERN1 (IRE1α), ATF4 (ATF4), XBP-1s, DDIT3 (CHOP)] at both mRNA and protein levels
(Figure 3A–D). Notably, this HA15-induced increase of UPR gene expr ssion (ATF4) did not occ r in
hFb16lu and Met-5A cells (Figure 3E). Mor over, HA15 treatment markedly augment d autophagic
genes [ATG5 (Autophagy protein 5), ATG7 (Autophagy protein 7), BECN1 (Beclin-1), and LC3B-II]
( igure 4A–C) and induced massive cell death in MESO-1 cells, marked by the time- and dose-dependent
i crease of pro-apoptotic markers [BCL2L11 (BIM), BBC3 (PUMA), and cleaved c spase 7 (Cl.Caspase
7)] (Figure 4A–C). Flow cytometry-based measurement of apoptotic cell populations confirmed that
the HA15 treatment resulted in MPM cell death in a dose-dependent manner (Figure 4D,E).
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Figure 3. HA15-induced ER stress activates malfunctional UPR in MPM cells. (A,B) qRT-PCR of
MESO-1 and BE261T cells after treatment with HA15 (10 uM) for the indicated time points. Data are
presented as mean ± s.d. (n = 3). * p < 0.05, ** p < 0.01, and **** p < 0.0001 by two-way ANOVA with
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Dunnett’s multiple comparisons test. (C,D) Western blots of MESO-1 and BE261T cells after treatment
with HA15 (20 uM) for the indicated time points. Quantification of the protein levels is shown under
each band, with signal intensity measured by ImageJ and normalized to the loading control (β-actin).
The value of the proteins in the vehicle group was set as 1. (E) Western blots of normal human lung
fibroblasts (hFb16Lu), normal human mesothelial (Met-5A), and MPM cells (MESO-1) after treatment
with HA15 (20 uM) for 24 h. Protein quantification is shown underneath, whereby signal intensity was
assessed by ImageJ and normalized to the loading control (β-actin), with the value of the DMSO group
set as 1.
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apoptosis. While HA15 dose-dependently decreased cell viability and concomitantly increased 
CHOP, apoptosis (cleaved caspase 7/PARP), and autophagy (LC3B-II/LC3B-I ratio) in MESO-1 cells 
with intact CHOP (siControl), CHOP depletion significantly attenuated HA15-induced growth 
inhibition, apoptotic, and autophagic indices in MESO-1 cells (Figures 4F,G). As expected, ATF4, 
which acts upstream of CHOP, was largely unaffected by CHOP downregulation and remained 
active in response to HA15 (Figure 4G). These data delineate that HA15 selectively triggers MPM cell 
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Figure 4. Activation of malfunctional UPR underpins HA15 efficacy in MPM cells. (A,B) qRT-PCR of
MESO-1 cells after treated with HA15 (10 uM) for the indicated time points. Data are presented as
mean ± s.d. (n = 3). * p < 0.05, ** p < 0.01, *** p < 0.005, and **** p < 0.0001 by two-way ANOVA with
Dunnett’s multiple comparisons test. (C) Western blots of MESO-1 cells after treatment with HA15
(20 uM) for the indicated time points. Quantification of the protein levels is shown under each band,
with signal intensity measured by ImageJ and normalized to the loading control (β-actin). The value of
the proteins in the vehicle group was set as 1. (D,E) FACS-based apoptotic assay of MESO-1 cells after
treatment with indicated doses of HA15 for 72 h. Data are presented as mean ± s.d. (n = 3). ** p < 0.01,
*** p < 0.005, and **** p < 0.0001 by two-way ANOVA with Dunnett’s multiple comparisons test.
A representative FACS plot is shown (E) with early and late apoptosis quantified by the Annexin V+/PI-
and Annexin V+/PI+ population, respectively. (F) MESO-1 cells transfected with the control (siCtrl) or
CHOP siRNAs (siCHOP) were treated with indicated doses of HA15. Cell viability was measured 48 h
after treatment (F). Data are presented as mean ± s.d. (n = 3). ** p < 0.01, and **** p < 0.0001 by two-way
ANOVA with Dunnett’s multiple comparisons test. (G) Cell lysates were prepared from MESO-1 cells
transfected with the control (siCtrl) or CHOP siRNAs (siCHOP) and analyzed by immunoblots. Protein
quantification is shown underneath, whereby signal intensity was assessed by ImageJ and normalized
to the loading control (β-actin), with the value of the DMSO group set as 1.
To test if the ER stress/UPR signaling axis is functionally important for HA15 effects on MPM cells,
we knocked down DDIT3 (encoding CHOP), a key effector of malfunctional UPR that leads to apoptosis.
While HA15 dose-dependently decreased cell viability and concomitantly increased CHOP, apoptosis
(cleaved caspase 7/P RP), and autophagy (LC3B-II/LC3B-I ratio) in MESO-1 cells with intact CHOP
(siControl), CHOP depletion significantly attenuated HA15-induced growth inhibition, apoptotic, and
autophagic indices in MESO-1 cells (Figure 4F,G). As expected, ATF4, which acts upstream of CHOP,
was largely unaffected by CHOP downregulation and remained active in response to HA15 (Figure 4G).
These data delineate that HA15 selectively triggers MPM cell death by inducing excessive ER stress
and the onset of malfunctional UPR and autophagy.
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2.4. HA15 Potently Inhibits Chemo-Resistant MPM Cells
To test if the effectiveness of HA15 can be extended to MPM cells resistant to standard chemotherapy,
we generated chemo-resistant MPM cells by chronic exposure to stepwise-increasing doses of
cisplatin/pemetrexed (Figure 5A). Both chemo-resistant (_R) and parental (_S) MPM cells responded to
HA15 in a dose-dependent manner (Figure 5B,C). Coherent with the results from parental chemo-naïve
MPM cells (Figure 3), HA15 induced excess ER stress, malfunctional UPR, and apoptotic cell death in
chemo-resistant MPM cells, gauged by significant upregulation of UPR genes (EIF2AK3, ERN1, ATF4,
DDIT3), autophagy (ATG5, BECN1), and pro-apoptosis [BCL2L11 (BIM), BBC3 (PUMA)] (Figure 5D–F).
Western blot analysis confirmed that HA15 invoked ER stress-activated malfunctional UPR (increased
p-eIF2α and CHOP) in chemo-resistant MPM cells (Figure 5G), which is known to lead to apoptosis.
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2.5. HA15 Suppresses MPM Tumor Growth In Vivo
Finally, we tested in vivo efficacy of HA15 through a comparison with standard chemotherapy
(cisplatin/pemetrexed (MTA) in a patient (BE261T)-derived xenograft (PDX) model of MPM. Whereas
HA15 and cisplatin/MTA alone delayed PDX tumor growth compared to the vehicle treatment, HA15
at the administrated dose exhibited greater anti-tumor effect than chemo (Figure 6A–C). Notably,
the efficacy of chemo was achieved at the cost of high toxicity, but HA15 at the used dose showed no
obvious side effects, monitored by body weights (Figure 6D) and a toxicity analysis that assessed liver
histology and hepatic transaminase (AST/ALT) activities in the treated mice (Figure 6E,F). Importantly
and in line with our in vitro results, PDX tumors after HA15 treatment displayed persistent activation
of ER stress-induced UPR (PERK, IRE1α, p-eIF2α, ATF4) and autophagy (Beclin-1, LC3B-II), which was
deemed anti-survival (CHOP), and enhanced cell death (Cl PARP, Cl Cas 7, Cl Cas 3) (Figure 6G,H).
Thus, pharmacological perturbation of ER stress/UPR signaling by HA15 shows stro anti-MPM
efficacy by inducing tumor cell death, validat HA15 as a potential therapeutic for MPM.
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Figure 6. HA15 suppresses MPM tumor growth in vivo. (A) Growth curves of patient (BE261T)-derived
xenograft (PDX) tumors treated with the vehicle, cisplatin/pemetrexed (3.75/83 mg/kg; chemo), or HA15
(0.7 mg/mouse) for the indicated time. Data are presented as mean ± SEM (n = 4). * p < 0.05, ** p < 0.01,
and **** p < 0.0001 by two-way ANOVA with Dunnett’s multiple comparisons test. (B,C) Tumor size (B)
and weights (C) of PDX (BE261T) tumors after e tr atment. Data are presented as mean ± SEM (n = 4).
* p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001 by one-way ANOVA with Dunnett’s multiple
comparisons test. (D) Mice body weights during treatment with HA15, chemo, or vehicle. Data are
presented as mean ± SEM (n = 4). * p < 0.05 by two-way ANOVA with Dunnett’s multiple comparisons
test. (E) Liver histology from treated mice. Original overall magnification, ×400. (F) Transaminase
(AST/ALT) activities of treated mice. Data are presented as mean ± SEM (n = 3). (G) Immunoblots of
PDX tumors after the treatment. Protein quantification is shown underneath, whereby signal intensity
was assessed by ImageJ and normalized to the loading control (β-actin), with the value of the vehicle
group set as 1. (H,E) Staining and IHC analysis for caspase-3 of PDX tumors after the treatment.
Original overall magnification, ×400.
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3. Discussion
We previously reported that dysregulated ER stress/UPR signaling is an important mechanism
underlying resistance to standard cisplatin/pemetrexed chemotherapy, and that further induction of
persistent ER stress overcomes chemo-resistance [26]. In this study, we discovered that deregulation of
ER stress/UPR signaling is a characteristic feature for MPM, which confers a therapeutic vulnerability
that normal mesothelial counterparts lack. We further demonstrated that pharmacologic augmentation
of ER stress by HA15 selectively targets MPM without apparent side effects in immune-deficient NSG
mice, leading to apoptotic cell death of MPM cells in vitro and potent suppression of MPM tumor
growth in preclinical mouse models. Mechanistically, HA15 induces excessive proteotoxic pressures
above the already high levels of ER stress in MPM, which embarks malfunctional UPR, autophagy, and
eventually activates programmed cell death. These results provide a therapeutic rationale by targeting
ER stress/UPR signaling in MPM and validate HA15 as a potential therapeutic for MPM.
Perturbation of ER stress/UPR can be achieved by pharmacological strategies, and small molecules
that target key components of the UPR machinery (e.g., the enzymatic activity of PERK (kinase), IRE1α
(RNAse) and the eukaryotic initiation factor eIF2α) have been investigated in preclinical studies [33].
Although pharmacological modulation of ER stress/UPR has demonstrated significant anti-tumor
activity in a variety of cancer models, undesired on-target side effects of ER stress modulators have
remained incompletely understood. For instance, chronic administration of PERK inhibitors has been
reported to impair pancreatic β-cells [34,35]. Furthermore, ER stress/UPR plays a key role in immune
surveillance [14]. As a consequence, deregulation of the IRE1α-XBP1 axis has been reported to account
for dysfunctional dendritic cells (DCs) and neutrophils [36], and CHOP is critical for the immune
inhibitory activity of tumor-infiltrating myeloid-derived suppressor cells (MDSCs) and of CD8+ T
cells [37,38].
Predominantly driven by pharmacologically intractable genetic alterations in tumor
suppressers [8–10], MPM remains the epitome of a lethal malignancy recalcitrant to targeted therapy
efforts. By capitalizing on an integrative approach, here, we discovered that ER stress/UPR signaling is
significantly deregulated in MPM compared to normal mesothelial cells. In particular, the molecular
chaperon BiP, a member of the heat shock protein 70 (HSP70) family and a master regulator of ER stress
response, is generally expressed at a high level in patients’ MPM and established MPM cell lines. BiP
cycles between the membrane and lumen of the ER, which functions as a molecular switch that senses
the magnitude of ER stress and sets the threshold for the onset of ER stress-responsive UPR [39]. As the
outcome of the UPR is bi-directional, pro-survival for readily relievable ER stress or pro-apoptotic if
persistent and incurable ER stress emanates, targeting ER stress signaling aimed at tipping the UPR
from a pro-survival to a pro-apoptotic mechanism, the latter executed by malfunctional UPR, has
emerged as a promising strategy of cancer therapy [26]. As proof of our finding, MPM cells, regardless
of chemotherapy-naïve or -resistant, were equally susceptible to HA15, a small molecule that induces
excess ER stress by specifically targeting BiP [29]. Indeed, the antitumor effect of HA15 is intimately
linked with its ability to augment UPR, as genetic depletion of CHOP, a master regulator of apoptotic
cell death elicited by malfunctional UPR, abrogates HA15 effectiveness in MPM.
In summary, it remains paramount to identify new and effective therapeutic approaches to
improve the clinical outcome of MPM patients. Our finding that deregulation of ER stress and the
adaptive UPR sensitizes MPM cells to agents that induce excess ER stress and alter the adaptive UPR
ushers in a therapeutically actionable strategy for MPM and supports further clinical investigations of
HA15 to treat patients with MPM, although the potential side effects of HA15 on immunity remains to
be addressed.
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4. Materials and Methods
4.1. Cell Culture and Reagents
Normal human lung fibroblasts hFb16Lu (CCD-16Lu, RRID: CVCL_2378), normal human
mesothelial cells Met-5A (MeT-5A, RRID: CVCL_3749), MPM cell lines H28 (NCI-H28, RRID:
CVCL_1555), H2452 (NCI-H2452, RRID: CVCL_1553), and H2052 (NCI-H2052, RRID: CVCL_1518) were
obtained from ATCC (American Type Culture Collection, Manassas, VA, USA). MPM cell lines MESO-1
(ACC-MESO-1, RRID: CVCL_5113) and MESO-4 (ACC-MESO-4, RRID: CVCL_5114) were obtained
from RIKEN Cell Bank (Ibaraki, Japan) [26,40–42]. MPM cell lines MSTO-211H (RRID: CVCL_1430)
and JL-1 (RRID: CVCL_2080) were purchased from DSMZ (German Collection of Microorganisms
and Cell Cultures, Brunswick, Germany). A primary MPM cell culture (BE261T) was established
from surgically resected tumors of a 67 year-old male patient using the same protocol as described
in [26,43] and used for short-term studies (up to eight passages in vitro). The human study was
performed under the auspices of protocols approved by institutional review board (KEK number:
042/15), and informed consent was obtained from patients. Cells were cultured in RPMI-1640 medium
or Medium 199 (Cat. #8758 and #4540; Sigma-Aldrich, St. Louis, MO, USA) supplemented with
10% fetal bovine serum/FBS (Cat. #10270-106; Life Technologies, Grand Island, NY, USA) and 1%
penicillin/streptomycin solution (Cat. #P0781, Sigma-Aldrich, St.Louis, MO, USA). All human cell
lines have been authenticated using STR profiling within the last three years and are confirmed
free from mycoplasma contamination (Microsynth, Bern, Switzerland). Cisplatin, pemetrexed/MTA
(Cat. #VL7640) and HA15 (Cat. #CS-5825) were obtained from Sandoz, Eli Lilly (Vernier, Suisse) S.A.
(Vernier/Geneva, Switzerland) and ChemScene (Monmouth Junction, NJ, USA), respectively.
Chemo-resistant cells (H28R, MESO-1R, and MESO-4R) were generated by chronic exposure to
cisplatin/MTA following a weekly schedule of 4-day treatment and 3-day recovery. Drug treatment
was initiated from cisplatin (0.1 µM) /MTA (0.5 µM) and increased in a stepwise manner until cisplatin
(3 µM) /MTA (5 µM). Induction of resistance was measured by the cell viability assay.
4.2. Cell Viability and Clonogenic Survival Assay
MPM cells seeded in 96-well plates (2500 cells/well) were dosed 24 h later with HA15 for 72 h.
Cell viability was determined by acid phosphatase (APH) assay as described [26,43,44]. The efficacy
of drugs on cell growth was normalized to the untreated control. Each data point was generated in
triplicate and each experiment was done three times (n = 3). Unless otherwise stated, a representative
result is presented. Best-fit curve was generated in GraphPad Prism [(log (inhibitor) vs. response
(-variable slope four parameters)]. Error bars are mean ± s.d.
Clonogenic assay was performed as described [26,43,44]. In brief, exponentially grown MPM cells
seeded in 6-well plates (1000 cells/well) were dosed 24 h later and continually treated with HA15 for
14 days (refresh drugs every three days), the resulting colonies were stained with crystal violet (0.5%
dissolved in 25% methanol). Growth curve was generated by eluting crystal violet staining with 10%
acetic acid and measuring absorbance at 590 nm. Three independent experiments were performed.
4.3. Quantitative Real-Time PCR (qRT-PCR)
Total RNA was isolated and purified by RNeasy Mini Kit (Cat. #74106; Qiagen, Germany).
Complementary DNA (cDNA) was synthesized by the high capacity cDNA reverse transcription
kit (Cat. #4368814; Applied Biosystems, Foster City, CA, USA), according to the manufacturer’s
instructions. Real-time PCR was performed in triplicate on a 7500 Fast Real-Time PCR System (Applied
Biosystems) with commercially available TaqMan ‘Assay on Demand’ primer/probes: EIF2AK3
(Hs00984005_m1), ERN1 (Hs00980095_m1), ATF4 (Hs00909569_g1), DDIT3 (Hs00358796_g1), BCL2
(Hs00608023_m1), BCL2A1 (Hs00187845_m1), BCL2L11 (Hs00708019_s1), BBC3 (Hs00248075_m1),
ATG5 (Hs00355492_m1), ATG7 (Hs00197348_m1), and BECN1 (Hs00186838_m1). The expression
of individual genes was normalized against GAPDH (Mm99999915_g1) using the ∆∆CT method.
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The baseline and threshold for CT calculation were set automatically with the 7500 software v2.06
(Thermo Fisher Scientific, Waltham, MA, USA).
4.4. Western Blot and Immunohistochemistry
Cell lysates were prepared and Western blot analysis was performed as described [26,43,44],
with the exception that protease inhibitors (Cat. #78440; Thermo Fisher Scientific, Waltham, MA,
USA) were included in lysis buffer. In brief, equal amounts of protein lysates (10–25µg/lane) were
resolved by SDS-PAGE (Cat. #4561033; Bio-Rad Laboratories, Hercules, CA, USA) and transferred
onto nitrocellulose membranes (Cat. #170-4158; Bio-Rad). Membranes were then blocked in blocking
buffer (Cat. #927-4000; Li-COR Biosciences, Bad Homburg, Germany) for 1 h at room temperature
and incubated with appropriate primary antibodies overnight at 4 ◦C. BiP (Cat. #3183S), IRE1α (Cat.
#3294S), PERK (Cat. #5683S), eIF2α (Cat. #5324S), Phospho-eIF2α (Ser 51) (Cat. #3398S), ATF4 (Cat.
#11815S), Beclin-1 (Cat. #3495S), LC3B (Cat. #12741S), PARP (Cat. #9532S), Cleaved-caspase 7(Cat.
#8438S) and Actin (Cat. #3700S) from CST (Cell Signaling Technology, Leiden, Netherlands). IRDye
680LT-conjugated goat anti-mouse IgG (Cat. #926-68020) and IRDye 800CW-conjugated goat anti-rabbit
IgG (Cat. #926-32211) from Li-COR Biosciences were used at 1:5000 dilutions. Finally, signals of
membrane-bound secondary antibodies were imaged using the Odyssey Infrared Imaging System
(Li-COR Biosciences).
Surgically removed xenograft tumors and liver sections were formalin-fixed and paraffin-
embedded (FFPE) and stained with hematoxylin and eosin (H&E) using standard protocols. FFPE
tumor blocks were sectioned at 4 µm, deparaffinized, rehydrated, and subsequently stained with an
appropriate antibody (Caspase 3, Cat. #9664, CST) using the automated system BOND RX (Leica
Biosystems, Newcastle, UK). Visualization was performed using the Bond Polymer Refine Detection kit
(Leica Biosystems) as instructed by the manufacturer. Images were acquired using PANNORAMIC®
whole slide scanners and processed using Case Viewer (3DHISTECH Ltd., Budapest, Hungary).
4.5. Apoptosis Assays
MPM cells were treated for 72 h with vehicle control or HA15. After treatment, cells in the
supernatant and adherent to plates were collected, washed with PBS, and pooled before suspended in
400 µL binding buffer and stained with the Annexin V Apoptosis Detection Kit-FITC (Cat. #88-8005;
Thermo Fisher Scientific, Waltham, MA, USA) according to the manufacturer’s instructions. Flow
cytometry analysis was performed on a BD Biosciences LSRII flow cytometer. Three independent
experiments were performed.
4.6. siRNA Knockdown
Knockdown of CHOP was achieved by specific duplex siRNAs (50 nmol/L) purchased from
Origene Technologies (Cat. #SR319903, Rockville, MD, USA). Transfection of siRNAs was performed
with SiTran1.0 (Cat. #TT300001, Origene Technologies, Rockville, MD, USA), according to the
manufacturer’s instructions.
4.7. In Vivo Mouse Study
Mouse studies were conducted in accordance with Institutional Animal Care and Ethical
Committee-approved animal guidelines and protocols. All mouse experiments were performed
in age- and gender-matched NSG (NOD-scid IL2Rγnull). Suspensions of tumor cells (in PBS) mixed
with 1:1 with BD Matrigel Basement Membrane Matrix (Cat. #356231; Corning Inc., Corning, NY,
USA) were subcutaneously inoculated in left and right flanks (BE261T cells: 1 × 106/injection). When
tumors were palpable, mice were randomly assigned to treatment groups: (1) control; (2) cisplatin
(3.75 mg/kg) plus pemetrexed (83 mg/kg) (i.p., once weekly) for five weeks; (3) HA15 (0.7 mg/mouse,
i.p., 5 days/week) for five weeks. Mice weight and tumor size were measured every three days. Tumor
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size was calculated as follows: (length × width × width)/2. At the endpoint, blood samples were
collected through cardiac puncta and subjected to the determination of transaminase activities.
4.8. Public Databases (GEO, GSEA, TCGA, EMBL-EBI) and UPR Gene Signature
Transcriptomic dataset of normal and MPM tumor samples (GSE2549 and GSE51024) were
downloaded from the Gene Expression Omnibus (GEO) database [31,32] and subjected to gene set
enrichment analysis (GSEA). Transcriptomic data of cancer patients were obtained from the Cancer
Genome Atlas (TCGA) (https://portal.gdc.cancer.gov/projects/TCGA). The expression of key UPR
genes in MPM cell lines were downloaded from the European Bioinformatics Institute of European
Molecular Biology Laboratory (EMBL-EBI, http://www.ebi.ac.uk/). The UPR status of tumors was
determined by the UPR gene signature, scored as the sum of the reactome unfolded protein response
gene set.
4.9. Statistical Analysis
Statistical analyses were performed using GraphPad Prism 7.01 (GraphPad Software Inc., San
Diego, CA, USA) unless otherwise indicated. All samples that met proper experimental conditions
were included in the analysis and sample size was not pre-determined by statistical methods, but
rather based on preliminary experiments. Group allocation was performed randomly. In all studies,
data represent biological replicates (n) and are depicted as mean values ± s.d. or mean values ± SEM as
indicated in the figure legends. Comparison of mean values was conducted with unpaired, two-tailed
Student’s t-test, one-way ANOVA, or two-way ANOVA with Tukey’s multiple comparisons test as
indicated in the figure legends. In all analyses, P values less than 0.05 were considered statistically
significant. Gene expression and survival data derived from the public database as well as the
correlation coefficient were analyzed using R (Version 3.4.3, https://cran.r-project.org/). For the survival
analysis, patients were grouped by gene expression, where ‘high’ and ‘low’ expression groups were
stratified by the optimal cut-off value.
5. Conclusions
Our study revealed that dysregulation of ER stress and adaptive UPR pathway is a characteristic
feature of MPM, and supports further investigation of HA15 as a novel therapeutic for patients
with MPM.
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